Posted in | News | Nanomedicine | Nanobusiness

Quest PharmaTech’s Nanoformulation of Photosensitizer Demonstrates Superior Anti-tumor Effect

Quest PharmaTech, a biotechnology firm specializing in cancer treatment products, has declared that the Journal of Photochemistry and Photobiology has accepted to publish a research paper titled ‘Antitumor Efficacy of Photodynamic Therapy Using Novel Nanoformulations of Hypocrellin Photosensitizer SL052.’

The paper covers the findings of a comparison study of the anti-cancer impact of the nano-formulation of SL052, a photosensitizer of Quest PharmaTech, against other earlier nano-formulation developed by the company in partnership with Edmonton-based IntelligentNano for photodynamic therapy. Researchers at the Vancouver-based BC Cancer Agency and the Saskatoon-based University of Saskatchewan carried out the study.

According to the findings, the novel nano-formulation of SL052 of Quest PharmaTech demonstrated superior anti-cancer impact when compared to the other nano-formulations. The study results were earlier reported in the Nanomedicine journal under the title ‘Water-Soluble and Biocompatible Sono/Photosensitizer Nanoparticles for Enhanced Cancer Therapy.’

Quest PharmaTech has submitted patent applications of these two nano-formulations and has started a preclinical study to assess their potential for curing gastrointestinal cancer by intravenously delivering the proprietary SL052 photosensitizer. These second-generation photodynamic therapy products of the company will support its current prostate cancer treatment initiative that uses the SL052 photosensitizer with an innovative intra-arterial drug delivery system.

The mechanism of Quest PharmaTech’s photo/sono-sensitizer based on innovative hypocrellin has been investigated in another study conducted by the University of Alberta and the findings were reported in the Journal of Investigational New Drugs under the title ‘Sonodynamic and Photodynamic Mechanisms of Action of the Novel Hypocrellin Sonosensitizer; SL017: Mitochondrial Cell Death is Attenuated by 11, 12-Epoxyeicosatrienoic Acid.’

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Chai, Cameron. (2019, February 12). Quest PharmaTech’s Nanoformulation of Photosensitizer Demonstrates Superior Anti-tumor Effect. AZoNano. Retrieved on June 25, 2024 from https://www.azonano.com/news.aspx?newsID=23884.

  • MLA

    Chai, Cameron. "Quest PharmaTech’s Nanoformulation of Photosensitizer Demonstrates Superior Anti-tumor Effect". AZoNano. 25 June 2024. <https://www.azonano.com/news.aspx?newsID=23884>.

  • Chicago

    Chai, Cameron. "Quest PharmaTech’s Nanoformulation of Photosensitizer Demonstrates Superior Anti-tumor Effect". AZoNano. https://www.azonano.com/news.aspx?newsID=23884. (accessed June 25, 2024).

  • Harvard

    Chai, Cameron. 2019. Quest PharmaTech’s Nanoformulation of Photosensitizer Demonstrates Superior Anti-tumor Effect. AZoNano, viewed 25 June 2024, https://www.azonano.com/news.aspx?newsID=23884.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.